Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer

NCT06134193 is registered in ClinicalTrials.gov with Union Hospital, Tongji Medical College, Huazhong University of Science and Technology as lead sponsor.

NCT NCT06134193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06134193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer
Lead sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2023
Completion date
June 30, 2025
Enrollment
41 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

angiogenesis inhibitors, antineoplastic agents, immunological, carcinoma, gallbladder cancer, immunotherapy, intrahepatic cholangiocarcinoma, surufatinib, tislelizumab